The U.S. Food and Drug Administration (FDA) recently announced a collaboration with Cerner Enviza, an Oracle Company, and John Snow Labs, an award-winning healthcare AI company, aimed at developing artificial intelligence (AI) tools to improve drug safety within electronic health records (EHRs) by “extracting critical information from EHR notes.” The partnership seeks to enhance the detection, monitoring, and analysis of drug safety data, ultimately improving patient care and public health.

Cerner Enviza is the continued development of Oracle’s acquisition and rebranding of Kantar Health, a division of Kantar Group ($375 million in cash). The unity of life sciences and real-world data aims to expedite the discovery, development, and delivery of extraordinary therapeutics. In 2008, the Sentinel Innovation Center (IC) “was created in response to FDA’s Medical Data Enterprise Initiative to build a new system containing electronic health records from 10 million lives and the Sentinel Five-Year Strategy.”

This collaboration will focus on creating AI algorithms capable of identifying potential drug safety issues within EHR data. By analyzing large volumes of patient data, these algorithms will detect patterns that may indicate adverse drug reactions or other drug-related safety concerns. The ultimate goal is to provide healthcare professionals with a more comprehensive understanding of potential drug risks, leading to more informed prescribing decisions and improved patient outcomes.

If you’re short on time:

The FDA’s Sentinel Innovation Center selected John Snow Labs and Cerner Enviza to develop AI tools for enhancing drug safety within EHRs. The collaboration will create algorithms to identify potential drug safety issues, helping healthcare professionals make informed prescribing decisions. The partnership seeks to improve patient care and public health by leveraging AI and EHR data.

Key Points:

  • The collaboration will extract EHR data driven by AI for drug safety surveillance
  • AI algorithms will help identify potential drug safety issues within EHR data
  • The partnership aims to improve patient care and public health by providing healthcare professionals with a comprehensive understanding of potential drug risks

The development of AI tools is said to address the growing need for advanced technology in drug safety surveillance. By harnessing the power of AI and EHR data, the partnership seeks to transform the way drug safety is monitored and managed.The FDA will focus on creating innovative solutions to streamline the drug safety process, making it more efficient and effective.

As healthcare organizations increasingly adopt EHRs and AI technology, the demand for Health IT professionals with expertise in AI, machine learning, and EHR systems is likely to rise. Staffing and recruiting firms specializing in Health IT will need to adapt to this growing demand, sourcing skilled talent to fill critical positions and support these transformative initiatives.

News of the developing collaboration highlights the importance of strategic partnerships between industry leaders, regulatory agencies, and technology providers in driving innovation and enhancing patient care through cutting-edge solutions.

Source: EHR Intelligence: FDA Selects Cerner Enviza to Develop EHR AI Tools for Drug Safety

Press Release (Oracle News): Cerner Enviza Collaborates with FDA to Develop Innovative AI Tools for Drug Safety and Real-World Evidence Studies